Navigation Links
Cylene to Present Advances in its Oral Inhibitor of CK2 at AACR Annual Meeting
Date:4/17/2009

SAN DIEGO, April 17 /PRNewswire/ -- Cylene Pharmaceuticals announced today that it will be presenting new data on recent advances of its small molecule anticancer agents during a symposium and several poster presentations at the American Association for Cancer Research (AACR) annual meeting, to be held on April 18-22 in Denver, Colorado.

Cylene scientists will unveil the first public description of CX-4945, a first-in-class oral inhibitor of protein kinase CK2. CK2 overexpression is well documented in many cancers and represents a previously unexploited molecular target. CX-4945 is a potent, selective inhibitor of CK2 and modulates key survival pathways in cancer cells. CX-4945, which has broad therapeutic potential in common cancers as well as in niche indications, has advanced rapidly into Phase I clinical trials.

The oral symposium will address the identification of pathway-specific biomarkers, while the posters will address the discovery and characterization of CX-4945 and the ability of CX-4945 to inhibit CK2-driven HIF-1alpha transcription and angiogenesis in hypoxia. In a separate poster, Dr. John Lim will describe the advancement of quarfloxin (CX-3543) into Phase II clinical trials in carcinoid/neuroendocrine tumors. The presentation schedule is:

Sunday, April 19, 2009: 8:00 AM CX-4945, a small molecule inhibitor of CK2, inhibits angiogenesis by affecting the vascular endothelium and suppressing hypoxia-activated HIF-1alpha transcription - Tumor Biology 2, Abstract 145

Tuesday, April 21, 2009: 8:00 AM Quarfloxin phase I clinical data and scientific findings supporting the selection of carcinoid/neuroendocrine tumors as the phase II indication - Clinical Research 12, Abstract 3599

Tuesday, April 21, 2009: 1:00 PM Discovery and characterization of CX-4945 a selective orally bioavailable small molecule inhibitor of pr
'/>"/>

SOURCE Cylene Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2
2. Trubion Pharmaceuticals, Inc. Announces Upcoming Presentation at the 2009 American Association of Cancer Research Annual Meeting
3. Cequent tkRNAi Technology to be Presented at the Centennial Meeting of the American Association for Cancer Research
4. Cynosure Announces Presentation of Favorable Results from Post-Marketing Studies of Smartlipo MPX
5. Interleukin Genetics Presents Research Linking Vertebral Fractures to Gene Variations in Asian Women With Osteoporosis
6. Novel Valortim(R) Mechanism of Action Data Presented at the Keystone Symposia on Molecular and Cellular Biology
7. NewCardio Leadership to Present Two Abstracts at ISCE Conference
8. RenalGuard(R) Pilot Safety Clinical Trial Data to be Presented at ACC 2009
9. Oramed Pharmaceuticals to Present Oral Insulin Phase 2A Trial Results at the Upcoming Annual Meeting of the ADA (June 5-9, New Orleans, LA)
10. Results From Efficacy and Safety Study of Cortheras Relaxin in Acute Heart Failure to be Presented at Late-Breaking Clinical Trials Session at ACC 58th Annual Scientific Session
11. ULURU Inc. to Present Altrazeal(TM) Clinical Evidence and Advanced Therapeutic Research at the Diabetic Foot Global Conference (DFCon) 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... YORK , May 22, 2013  The Lupus ... conference devoted to advancing new treatments for lupus nephritis, ... 60 percent of patients. The conference launched a new ... the Lupus Nephritis Trials Network (LNTN). More ... and the kidney came together to focus on two ...
(Date:5/22/2013)... May 22, 2013  Modern Medical announced today ... Launched in November 2012 in a test phase, ... to stop the rising opioid abuse in the ... program designed to protect employees, physicians and employers ... necessary balance to provide pain relief for the ...
(Date:5/22/2013)... , May 22, 2013  MGT Capital Investments, Inc. ... present at the Second Annual Marcum LLP MicroCap Conference ... York City at the Grand Hyatt Hotel.  ... Executive Officer, will update investors and answer questions. ... Company,s presentation is scheduled to begin at 9:30 a.m. ...
Breaking Medicine Technology:Lupus Research Institute Hosts First International Conference to Advance New Treatments for Lupus Nephritis 2Modern Medical Introduces Opioid Abuse Solution to the Workers' Compensation Industry 2MGT Capital Investments, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 2MGT Capital Investments, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 3MGT Capital Investments, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 4
... Kosan Biosciences,Incorporated (Nasdaq: KOSN ) today announced ... lead Hsp90 inhibitor, from a Phase,2 trial in combination ... the 2008 Annual Meeting of the American,Society of Clinical ... 31 through June 3, 2008., Abstract 1027, titled, ...
... Spain, May 13 ,Boston Scientific Corporation (NYSE: ... the SPIRIT III clinical trial, which continue ... of the market-leading TAXUS(R) Express2(TM),Paclitaxel-Eluting Coronary Stent ... clinical evidence for the XIENCE(TM) V (PROMUS(TM)),Everolimus-Eluting ...
Cached Medicine Technology:Kosan Announces Data Presentations at ASCO 2008 Annual Meeting 2Kosan Announces Data Presentations at ASCO 2008 Annual Meeting 3SPIRIT III Results Reaffirm Strong Performance of Boston Scientific PROMUS(TM) and TAXUS(R) Express(R) Stents 2SPIRIT III Results Reaffirm Strong Performance of Boston Scientific PROMUS(TM) and TAXUS(R) Express(R) Stents 3SPIRIT III Results Reaffirm Strong Performance of Boston Scientific PROMUS(TM) and TAXUS(R) Express(R) Stents 4
(Date:5/22/2013)... of Michigan study challenges previous research that suggests ... The study, a collaboration between researchers at U-M ... deeper into the controversial argument over whether MLB ... pitchers of the same race. It found little ... Winfree, associate professor of sport management at the ...
(Date:5/22/2013)... -- Over the next two decades, the cost of ... more than double, topping more than $180 billion a ... driving the increase: an aging population. The report, from ... Association, was published May 22 in the journal ... care system," Dr. Bruce Ovbiagele, chairman of the department ...
(Date:5/22/2013)... researchers report that hospitals may be reaping enormous ... by preventable bloodstream infections contracted in their intensive ... reported online in the American Journal of ... ICU patient who develops an avoidable central line-associated ... to care for than a similar infection-free patient. ...
(Date:5/22/2013)... May 22, 2013 Phelps Memorial Hospital ... Westchester Lung Nodule Center for individuals who would ... cancer care. Lung cancer is the deadliest form of cancer ... in the U.S. die from lung cancer than from breast, ... cancers, early detection increases survival rates. It is well ...
(Date:5/22/2013)... 22, 2013 Hurricane preparation isn’t just ... That’s why Amica Insurance is reminding everyone ... upcoming hurricane season. , “An important part of hurricane ... a senior assistant vice president at Amica Insurance. “The ... the threat of a storm.” , Flood damage is ...
Breaking Medicine News(10 mins):Health News:U-M study challenges notion that umpires call more strikes for pitchers of same race 2Health News:Cost of Treating Strokes in U.S. Could Soar to $180B Annually by 2030: Report 2Health News:Cost of Treating Strokes in U.S. Could Soar to $180B Annually by 2030: Report 3Health News:Hospitals profit when patients develop bloodstream infections 2Health News:Hospitals profit when patients develop bloodstream infections 3Health News:Hospitals profit when patients develop bloodstream infections 4Health News:Phelps Memorial Hospital Center Establishes The Westchester Lung Nodule Center To Diagnose And Administer Lung Cancer Care 2Health News:Phelps Memorial Hospital Center Establishes The Westchester Lung Nodule Center To Diagnose And Administer Lung Cancer Care 3Health News:Reviewing Insurance Policies: a Key Part of Hurricane Preparations 2
... music industry,veteran and TV personality, is coming to ... about type 2 diabetes and its connection to,cardiovascular ... to speak on behalf of a national campaign, ... type 2 diabetes manage the disease,and reduce the ...
... ANSS ), a global innovator of simulation ... today announced it is a,sponsor of the Dinosaurs ... of,Natural History in Pittsburgh. This is the first ... immersive environments that are,composed of original fossil specimens. ...
... 17 NBTY, Inc. (NYSE:,NTY) (http://www.NBTY.com ), a ... that it will web cast the,presentation by Harvey Kamil, ... Small And Mid-Cap Conference in Las Vegas on,Wednesday, March ... web cast live on the Company Web,site, http://www.nbty.com ...
... chemokine receptor believed ... role in Crohn,s disease -, CAMBRIDGE, Mass., March 17 ... advancement of,MLN3126, a new product candidate, from the Company,s discovery ... CCR9, a,chemokine receptor known to be important in the migration ...
... Studies Now Available to the Public, ... Corporation,today announced the release of InSight(TM), a ... and sharpens the brain,s ability to process,visual ... just visual,processing abilities, but also increases driving ...
... Researchers will unveil a,new brain fitness ... in numerous,published studies to help people maintain ... of daily living tasks essential to,independence. The ... San,Francisco-based neuroscience company, will introduce the new ...
Cached Medicine News:Health News:Randy Jackson and the American Heart Association Educate Raleigh Area Residents About the Connection Between Type 2 Diabetes and Cardiovascular Disease 2Health News:Randy Jackson and the American Heart Association Educate Raleigh Area Residents About the Connection Between Type 2 Diabetes and Cardiovascular Disease 3Health News:ANSYS Sponsors Dinosaurs Exhibit at Carnegie Museum of Natural History 2Health News:ANSYS Sponsors Dinosaurs Exhibit at Carnegie Museum of Natural History 3Health News:NBTY to Web Cast Presentation at Citigroup Small and Mid-Cap Conference 2Health News:Millennium Expands IBD Franchise with Addition of New Development Candidate 2Health News:Millennium Expands IBD Franchise with Addition of New Development Candidate 3Health News:New Brain Training Program Improves Quality of Life 2Health News:New Brain Training Program Improves Quality of Life 3Health News:New Brain Fitness Training Promotes Health and Independence of Long Term Care Insurance Policyholders 2Health News:New Brain Fitness Training Promotes Health and Independence of Long Term Care Insurance Policyholders 3
... EnVision Autoclavable Camera Head with an integrated coupler ... Made of a non-metallic material, it is cool ... just minutes. This product incorporates Smarthead technology allowing ... number of times the camera head has been ...
... 1-Chip Camera System provides easy-to-use features, auto ... scope. The camera head construction is based ... 14, Complete 1-Chip Camera System, International (GS ... Unit (CCU) with video cables , (GS ...
... offers 800+ lines of resolution along with color ... white balance features in a user-friendly design. , ... includes: , (GS 9923) Camera Control Unit (CCU) ... head with 3 meter cable (10 ft.)(1/2" format ...
Provides a combination of concentrated cold / hot and compression for the neck...
Medicine Products: